Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp Inks Companion Dx Pact with Vanda

NEW YORK (GenomeWeb News) – Laboratory Corporation of America said today that it will develop and distribute a series of diagnostic tests that will be companions for a schizophrenia drug made by Vanda Pharmaceuticals.
 
The tests will be based on a series of genetic markers Vanda discovered while developing an antipsychotic drug that is now undergoing review by the US Food and Drug Administration.
 
Under the agreement, LabCorp will be Vanda’s exclusive commercialization partner for companion tests for the drug iloperidone, which the company plans to market under the name Fanapta.
 
Financial terms of the agreement were not released.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.